Vertex Pharmaceuticals has spent more than 20 years discovering, researching and developing medicines to treat the underlying cause of cystic fibrosis.

Dec 20, 2024 · Clinical trial results for Alyftrek showed improvements in lung function comparable to those seen with Trikafta, and a reduction in sweat chloride levels that exceeded treatment …

Explore treatment options offered by Vertex and find out if your patients with cystic fibrosis (CF) are eligible based on their age and mutations. Please see Indications and Important Safety …

Dec 20, 2024 · ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the …

Facts about cystic fibrosis (CF), including prevalence and the numbers of people with CF around the world estimated to be on CFTR modulators

Dec 20, 2024 · TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane …

Vertex offers several cystic fibrosis (CF) treatment options for individuals of certain ages with specific CF gene mutations. While not everyone with CF is eligible for a Vertex treatment …

Feb 5, 2024 · Set the bar and then beat it; that's what Vertex Pharmaceuticals has just done with a next-gen cystic fibrosis (CF) treatment. The investigational treatment is a once-daily triple …

Jan 2, 2025 · The Food and Drug Administration ended 2024 with a quartet of notable drug approvals, including three of new medicines that Vertex Pharmaceuticals, Novo Nordisk and …

May 7, 2024 · Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple. Vertex completed the regulatory …